Some friends and I are discussing our favorite foods. “What’s yours?” one of them asked me. I can feel the answer, beyond the horizon of my mind, but out of reach. My heart starts pounding; I start to feel dizzy.
Anyone over the age of 50 has probably experienced some version of this so-called “big moment.” The more often it happens, the more fear is created. Anxiety is widespread. Among neurocognitive disorders, none is more visible among the public imagination than Alzheimer’s disease. According to recent estimates, it may rank as the third leading cause of death among older adults in North America, after heart disease and cancer.
Twenty years ago, a widely cited journal article Nature Alzheimer’s has been linked to the accumulation of abnormal proteins, particularly the sticky beta-amyloid that forms plaques outside neurons and tau tangles, or misfolded proteins inside them. Together, they disrupt cell communication and cause cell death.
For the past two decades, the amyloid hypothesis has dominated the field, guiding countless clinical trials and drug development programs. However, the results were disappointing. Despite major efforts, progress in prevention and treatment has been modest at best. Increasingly, researchers are exploring alternative explanations, new ways of thinking about disease that seem uncooperative to understand.
According to some estimates, 40 percent dementia All over the world, conditions (including Alzheimer’s) are associated with risk factors that can change, at least over a lifetime. Exploring these modifiable factors and what practical steps we can take to support healthy brain aging will be the subject of my next post. Today we review the latest research on the biology and diagnosis of this condition.
An Appetite For energy
One new area of research concerns the brain’s incredible appetite for energy. Every thought, every one memoryrequires neurons to fire and communicate, a process powered by ATP, or adenosine triphosphate, the key molecule for storing and transmitting energy in all living cells. It powers important processes such as muscle contraction, nerve impulses, and chemical synthesis. Produced by ATP mitochondriamicroscopic power plants inside our cells. When mitochondrial function declines, neurons struggle to meet energy demands.
Interesting experiments with fruit flies and mice show that boosting mitochondrial energy production can improve memory formation. Metabolically enhanced animals were able to form long-term memories lasting more than 24 hours after a single encounter with a stimulus, bypassing the usual need for repeated training. The findings suggest that even simple improvements in cellular energy supply can affect how memories are consolidated, which has obvious implications for Alzheimer’s.
Researchers at the University of Porto in Portugal are investigating treatments aimed at restoring mitochondrial health. Proposed strategies include targeted antioxidants, drugs that stimulate mitochondrial biogenesis, and compounds that stabilize mitochondrial dynamics. By preserving the cell’s energy machinery, such treatments may slow or reverse the course of neurodegenerative disease.
Alzheimer’s research has traditionally focused on immune activity within the brain itself, particularly among resident immune cells such as microglia. Immune cells that originate outside the brain expand and enter the cerebrospinal fluid in Alzheimer’s patients, researchers at Northwestern University have found. The reason this is so important is that it helps expand the focus of research beyond brain-resident immune cells such as microglia to include systemic immune cells and provide new therapeutic targets for disease treatment.
Complex work
Diagnosing Alzheimer’s disease remains a complex task. Clinicians rely on taking a careful clinical history, cognitive testing, laboratory work, and increasingly sophisticated imaging techniques. These include magnetic resonance imaging, which shows shrinkage of the hippocampus, a brain structure important for memory and one of the earliest regions often affected. More specialized and more expensive, positron emission tomography can detect amyloid plaques or tau deposits, providing early insight into brain pathology. In some cases, doctors may also analyze cerebrospinal fluid obtained through a lumbar puncture.
In May 2025, the US Food and Drug Administration approved the first blood test designed to detect biomarkers It is intended for people age 55 and older who are showing signs of cognitive decline related to Alzheimer’s. The test measures phosphorylated tau protein (pTau217) and amyloid-beta ratio specifically to detect Alzheimer’s-related brain changes, offering a less invasive alternative to PET scans or lumbar punctures. Clinical studies have shown that a positive result has a high correlation (more than 90 percent) with the presence of amyloid plaque, while a negative result helps to rule out the disease. It is intended to be used by physicians in conjunction with other clinical assessments, not as a stand-alone test.
In the coming years, there will be more research that will bring us closer to reliable early diagnosis.
However, a word of warning. Early diagnosis is not a blessing. Learning that there is a person mild cognitive impairment The condition associated with Alzheimer’s disease can be both calming and disturbing. Some people welcome knowledge. This allows them to make financial arrangements, advance care instructions and talk to long-lost family members. Others find the information troubling, especially given the lack of a clear cure.
In addition, the diagnosis, even at this age AIis an educated guess only. Two people with almost the same brain scan can function completely differently in everyday life. Educationcognitive reserve, social networks, and the presence of other medical conditions shape how symptoms develop. The body, especially the brain, retains something amazing even under siege endurance.
As Yogi Berra said, “It’s hard to spring, especially about the future.”
